Skip to main content
Intermediate Formal

Collaborative Melanoma Study

Alternative reference to COMS, the landmark multi-center randomized clinical trial that established treatment standards for choroidal melanoma.

Full Definition

The Collaborative Melanoma Study, more commonly referenced by its acronym COMS (Collaborative Ocular Melanoma Study), represents the most significant randomized clinical trial in ocular oncology history. This multi-institutional study, conducted from 1986 to 1994, enrolled over 2,400 patients and established evidence-based treatment guidelines for choroidal melanoma management. The study consisted of three randomized trials comparing enucleation versus plaque radiotherapy for medium tumors, pre-enucleation radiation versus enucleation alone for large tumors, and observation versus immediate treatment for small melanomas. Results demonstrated equivalent survival outcomes between enucleation and plaque radiotherapy for medium-sized tumors while preserving the eye, fundamentally changing clinical practice worldwide.

Usage

Usage note: May be abbreviated as COMS; emphasize landmark status in melanoma treatment standards.

In Context

  • "Treatment recommendations followed protocols established by the Collaborative Melanoma Study for medium-sized choroidal melanomas." — Treatment planning note
  • "The Collaborative Melanoma Study demonstrated non-inferiority of plaque radiotherapy compared to enucleation for survival outcomes." — Literature review

Also known as

COMS study Collaborative Ocular Melanoma Study

Don't confuse with

Collaborative Ocular Melanoma Study Group

Editors from these organisations have used our services since 1998

Reuters BBC Oxford University Press Penguin Random House Springer Microsoft Suncor Energy United Nations Fisher Investments IBM The Home Depot KODAK CHEVRON